地赐康治疗高脂血症的临床观察

Clinical evaluation of dicikang in treatment of hyperlipidemia

目的 :观察地赐康的降血脂疗效。方法 :90例原发性高血脂症患者随机分为 2组。治疗组 6 0例给予地赐康冲剂 1袋 ,tid ;对照组 30例给予血脂康胶囊 2粒 ,bid。疗程 8周。结果 :治疗 8周后 ,治疗组血清总胆固醇(TC)、血清低密度脂蛋白 (LDL C)、甘油三酯 (TG)水平分别下降了 2 2 .3% (P <0 .0 0 1) ,30 % (P <0 .0 1) ,18.8%(P <0 .0 5 ) ,载脂蛋白A1水平升高了 11.9% (P <0 .0 1) ;载脂蛋白B(ApoB)和脂蛋白 (a) (LP(a) )分别下降了 8%和31.3% (P <0 .0 1)。与对照组检测指标基本相似 ,2组间未见有统计学意义的差异。且治疗组用药期间未出现明显不良反应。结论 :地赐康是一种有效的血脂调节剂 ,且依从性好 ,服用安全。

Objective:To observe the efficency of Dicikang for the treatment of hyperlipidemia.Methods:90 patients with primary hyperlipidemia were randomly allocated into two groups.Group 1 consisted of 60 patients,each took Dicikang sack tid for 8 weeks; Group 2 included 30 patients ,each took 2 Xuezhikang capsulesbid for 8 weeks.Results:After treatment for 8 weeks,in group 1,the serum level of total cholesterd(TC),low density lipoprotein cholesterol(LDL C),triglyceride(TG) were reduced by 22.3%( P <0.001),30%( P <0.01),18.8%( P <0.05).ApoA 1 was elevated by 11.9%( P <0.01),ApoB and LP(a) were reduced by 8% and 31.3%( P <0.01).There was no obvious difference between two groups,no statistical significance was found between two groups and no significant dysresponse and side effect were found in the duration of treatment.Conclusion:Dicikang is an effective lipid regulator and has a good compliance and reliability.